News & Updates

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.

Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.

According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong. 

A study from Israel validated the safety of the fourth BNT162b2 mRNA COVID-19 vaccine (ie, second booster) using data from a retrospective and a prospective cohort.

Full vaccination with the SARS-CoV-2 BNT162b2 vaccine reduced infection and hospitalization due to the delta and omicron variants of the SARS-CoV-2 infection, with an added benefit against the omicron variant in individuals who received a booster dose, according to a national study of Singaporean adolescents.

Patients with mild COVID-19 may encounter a few health concerns for several months following SARS-CoV-2 infection, but these outcomes tend to resolve within a year from diagnosis, reveals a study.

The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.